Clinical trial
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02435849 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02435849 |
|---|---|
| Title | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients |
| Official title | A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia |
| Acronym | ELIANA |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Acute Lymphoblastic Leukemia |
| Intervention type | Biological |
| Interventions | CTL019 |
| Enrollment | 80 |
| Start date | Apr 8, 2015 |
| Primary completion | Jan 21, 2020 |
| Completion | Nov 17, 2022 |
| First posted | May 6, 2015 |
| Last update posted | Feb 13, 2024 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Norway, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: